Medical Condition News

RSS

New data on implementation of minimally invasive treatments for ruptured intracranial aneurysms

Two recent studies from the Zeenat Qureshi Stroke Research Center, in Minneapolis, MN, provide new data regarding implementation of minimally invasive treatments for ruptured intracranial aneurysms and impact on patient outcomes in U.S.

11 Oct 2010

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

Fat-free popcorn may help dieters maintain reduced calorie eating plans

ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.

11 Oct 2010

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

Attorney Keith Jensen of the Fort Worth, Texas-based law firm of Jensen, Belew & Gonzalez is announcing a $3.78 million settlement with pharmaceutical manufacturer Pfizer Inc. on behalf of the family of a nine-year-old New York girl who died in June 2004 as the result of a drug-induced disease known as Stevens Johnson Syndrome, which caused all of her skin to peel off.

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

Varian and Stanford scientists receive $3.6M NIH grant to develop advanced imaging technology

Scientists from Stanford University and from the Ginzton Technology Center at Varian Medical Systems have jointly received a $3.6 million five-year research grant from the U.S. National Institutes of Health (NIH) to develop advanced imaging technology for improving the quality of CT images for patients with metal objects in their bodies such as hip implants and dental fillings.

11 Oct 2010

Gelesis presents lead products data at Obesity 2010 Annual Meeting

Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.

11 Oct 2010

IRIDEX introduces new family of Adjustable & Intuitive EndoProbe laser handpieces

IRIDEX Corporation today announced commercial availability of a new family of Adjustable & Intuitive EndoProbe laser handpieces for use with the Company's laser platforms in vitreoretinal surgery.

11 Oct 2010

ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC

ArQule, Inc. today announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a Phase 3 trial of ARQ 197 in patients with non-small cell lung cancer (NSCLC) of non-squamous histology.

11 Oct 2010

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

MingSight Pharmaceuticals announced today that it has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases.

11 Oct 2010

Prescription Solutions' MS DTM program wins URAC Best Practices Platinum Award

Prescription Solutions, a leading pharmacy benefits management (PBM) organization and a UnitedHealth Group company, received a platinum award in the URAC Best Practices in Health Care Consumer Empowerment and Protection Awards. Prescription Solutions was recognized for its Multiple Sclerosis Disease Therapy Management (MS DTM) program, which empowers patients through education and support to successfully attain skills in self-managing their symptoms and medication therapy for their chronic condition.

11 Oct 2010

Genta announces EMA Orphan Drug designation for tesetaxel

Genta Incorporated today announced that tesetaxel, the leading oral taxane in clinical development, has been designated as an Orphan Drug by the European Medicines Agency for gastric cancer. The drug has previously received Orphan Drug designation by the U.S. Food and Drug Administration for both gastric cancer and melanoma, as well as Fast Track designation by FDA for gastric cancer.

11 Oct 2010

Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis

Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).

11 Oct 2010

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).

11 Oct 2010

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).

11 Oct 2010

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Geron Corporation today announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.

11 Oct 2010

Researchers to convene for 2010 Advances in Breast Cancer Research Workshop at University of Arkansas

Leading national researchers in the fight against breast cancer will convene Oct. 26-29 for the 2010 Advances in Breast Cancer Research Workshop at the University of Arkansas. More than 70 scientists from diverse research areas in science, medicine, engineering and technology will participate. Ten featured speakers will present cutting-edge research on breast cancer diagnosis, therapeutic techniques, treatment and screening.

11 Oct 2010

NIH selects Neil Chi for 2010 New Innovator Award

The National Institutes of Health has chosen Neil Chi, MD, PhD, assistant professor of medicine in the division of cardiology at the University of California, San Diego, as one of its 2010 NIH Director's New Innovator Award recipients.

11 Oct 2010

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Medical Condition News

New data on implementation of minimally invasive treatments for ruptured intracranial aneurysms

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Fat-free popcorn may help dieters maintain reduced calorie eating plans

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Varian and Stanford scientists receive $3.6M NIH grant to develop advanced imaging technology

Gelesis presents lead products data at Obesity 2010 Annual Meeting

IRIDEX introduces new family of Adjustable & Intuitive EndoProbe laser handpieces

ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

Prescription Solutions' MS DTM program wins URAC Best Practices Platinum Award

Genta announces EMA Orphan Drug designation for tesetaxel

Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

AVEO presents tivozanib Phase 2 study results at ESMO Congress

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Researchers to convene for 2010 Advances in Breast Cancer Research Workshop at University of Arkansas

NIH selects Neil Chi for 2010 New Innovator Award

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News